<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00064285</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000310175</org_study_id>
    <secondary_id>U01CA062502</secondary_id>
    <secondary_id>MCV-NCI-6013</secondary_id>
    <secondary_id>MCV-VCU-1902</secondary_id>
    <secondary_id>NCI-6013</secondary_id>
    <secondary_id>CWRU-030323</secondary_id>
    <nct_id>NCT00064285</nct_id>
  </id_info>
  <brief_title>Flavopiridol and Imatinib Mesylate in Treating Patients With Hematologic Cancer</brief_title>
  <official_title>Phase I Study Of Flavopiridol In Combination With Imatinib Mesylate (STI571, Gleevec) In Bcr/Abl+ Hematological Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes&#xD;
      necessary for cancer cell growth. Drugs used in chemotherapy such as flavopiridol use&#xD;
      different ways to stop cancer cells from dividing so they stop growing or die. Combining&#xD;
      imatinib mesylate with flavopiridol may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of flavopiridol and&#xD;
      imatinib mesylate in treating patients with hematologic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose and recommended phase II dose of flavopiridol and&#xD;
           imatinib mesylate in patients with Bcr/Abl+ hematological malignancies.&#xD;
&#xD;
        -  Determine the toxic effects of this regimen in these patients.&#xD;
&#xD;
        -  Determine the disease-related effects of this regimen in these patients.&#xD;
&#xD;
        -  Determine the pharmacokinetics and pharmacodynamics of this regimen in these patients.&#xD;
&#xD;
        -  Correlate response to this regimen with mechanisms of imatinib mesylate resistance in&#xD;
           patients previously treated with imatinib mesylate.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation, multicenter study. Patients are stratified according to&#xD;
      percentage of blasts in the peripheral blood and bone marrow (less than 15% vs at least 15%)&#xD;
      and recent myelosupressive treatment (no vs yes).&#xD;
&#xD;
      Patients receive oral imatinib mesylate daily and flavopiridol IV over 1 hour on days 2, 9,&#xD;
      and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of imatinib mesylate and flavopiridol until&#xD;
      the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that&#xD;
      at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 6-80 patients will be accrued for this study within 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">22</enrollment>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alvocidib</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>imatinib mesylate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of 1 of the following:&#xD;
&#xD;
               -  Chronic or accelerated phase chronic myelogenous leukemia (CML) with 1 of the&#xD;
                  following:&#xD;
&#xD;
                    -  Hematologic progression during prior imatinib mesylate treatment&#xD;
&#xD;
                    -  Less than a complete hematologic response after at least 3 months of prior&#xD;
                       imatinib mesylate treatment&#xD;
&#xD;
                    -  Less than a major cytogenetic response after at least 6 months of imatinib&#xD;
                       mesylate treatment (cytogenetic response documented by karyotype or&#xD;
                       fluorescence in situ hybridization [FISH])&#xD;
&#xD;
               -  Blastic phase CML*&#xD;
&#xD;
               -  Acute lymphoblastic leukemia*&#xD;
&#xD;
               -  Acute myeloid leukemia* NOTE: *Patients may be enrolled at presentation, in&#xD;
                  remission, or upon relapse&#xD;
&#xD;
          -  Bcr/Abl+ in bone marrow confirmed by karyotype or FISH&#xD;
&#xD;
          -  No known CNS malignancy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT no greater than 2.5 times ULN (5 times ULN if hepatic involvement&#xD;
             suspected [stratum 2 only])&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 2 times ULN&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months after study&#xD;
             participation&#xD;
&#xD;
          -  No prior allergic reaction attributed to compounds of similar chemical or biological&#xD;
             composition to study agents&#xD;
&#xD;
          -  No other concurrent uncontrolled medical illness&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent filgrastim (G-CSF), sargramostim (GM-CSF), or interleukin-2 during the&#xD;
             first course of study therapy unless clinically indicated for management of febrile&#xD;
             neutropenia or thrombocytopenia&#xD;
&#xD;
          -  Concurrent epoetin alfa allowed if started before study entry and it remains&#xD;
             clinically appropriate&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Recovered from all prior therapy&#xD;
&#xD;
          -  No other concurrent investigational or anticancer agents&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Grant, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Massey Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ireland Cancer Center at University Hospitals of Cleveland and Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5047</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massey Cancer Center at Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <study_first_submitted>July 8, 2003</study_first_submitted>
  <study_first_submitted_qc>July 8, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2003</study_first_posted>
  <last_update_submitted>April 30, 2010</last_update_submitted>
  <last_update_submitted_qc>April 30, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 3, 2010</last_update_posted>
  <responsible_party>
    <organization>National Cancer Institute</organization>
  </responsible_party>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>untreated adult acute myeloid leukemia</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>adult acute lymphoblastic leukemia in remission</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>untreated adult acute lymphoblastic leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
    <mesh_term>Alvocidib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

